Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.
Neehar Parikh, MD, medical director, Multidisciplinary Liver Tumor Clinic, medical director, Living Donor Liver Transplantation Program, assistant professor, University of Michigan Health, Michigan Medicine, discusses future research directions in hepatitis C-related hepatocellular carcinoma (HCC).
During the 2021 International Liver Cancer Association Annual Conference, findings from a retrospective cohort study were presented virtually. Moving forward, these analyses could be updated should additional systemic therapies get introduced to the HCC armamentarium to determine whether these agents induce a survival benefit in patients with hepatitis C-related HCC, Parikh says. However, this would be difficult to conduct prospectively at this point.
Additionally, hepatitis C is becoming an increasingly rare etiologic cause of HCC and cirrhosis because of improved screening and direct-acting antiviral therapies, Parikh explains.
Although less patients are presenting with viremic hepatitis C, this analysis serves to fulfill an unmet need. Additionally, it remains beneficial to explore other cohort studies to observe patients with active, treated hepatitis C-related HCC to determine how treatment affects outcomes, Parikh concludes.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
2 Commerce Drive
Cranbury, NJ 08512